Related Experiment Videos
The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor
D A Lappi1, P A Maher, D Martineau
1Department of Molecular and Cellular Growth Biology, Whittier Institute for Diabetes and Endocrinology, La Jolla, California 92037.
Journal of Cellular Physiology
|April 1, 1991
Summary
A novel mitotoxin, basic fibroblast growth factor-saporin (FGF-SAP), selectively targets the FGF receptor, inhibiting cell growth and protein synthesis. This receptor-specific compound shows potential as a therapeutic anti-FGF agent.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Basic fibroblast growth factor (FGF) plays a crucial role in cellular processes.
- Targeting FGF signaling is a potential therapeutic strategy for various conditions.
Purpose of the Study:
- To confirm that a mitotoxin, basic fibroblast growth factor-saporin (FGF-SAP), exerts its cytotoxic effect via specific interaction with the FGF receptor.
- To evaluate the potency and specificity of FGF-SAP as a receptor antagonist.
Main Methods:
- Utilized cross-linking experiments to demonstrate FGF-SAP binding to the FGF receptor.
- Assessed cytotoxicity through inhibition of protein synthesis, DNA synthesis, and cell count.
- Investigated the effect of receptor number on mitotoxin efficacy across different cell types.
Main Results:
- FGF-SAP specifically binds to the FGF receptor and stimulates downstream signaling (tyrosine phosphorylation).
- Suramin, an FGF receptor binding inhibitor, blocked FGF-SAP cytotoxicity.
- Mitotoxin efficacy (ED50) increased with higher FGF receptor numbers per cell.
- FGF-SAP rapidly inhibited cell count, protein, and DNA synthesis.
Conclusions:
- The mitotoxin FGF-SAP acts as a potent, receptor-specific suicide antagonist of basic FGF.
- FGF-SAP demonstrates significant in vitro cytotoxicity through targeted FGF receptor interaction.
- FGF-SAP holds potential for therapeutic and research applications as an anti-FGF agent.